Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-A-1041 in HER2-Positive Advanced Solid Tumors
NCT05593094Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Aug 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 2, open-label trial of ZN-A-1041 in solid tumor and breast cancer (7 arms), sponsored by Roche. Primary endpoints: Incidence of Treatment-emergent Adverse Events at 21 days and Recommended Phase 2 Dose at 1 year. Started Sep 2020; status: active, not recruiting.
02
Drugs
ZN-A-1041
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT05593094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593094.